310 related articles for article (PubMed ID: 22564993)
1. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
[TBL] [Abstract][Full Text] [Related]
2. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
Niraula S; Dowling RJ; Ennis M; Chang MC; Done SJ; Hood N; Escallon J; Leong WL; McCready DR; Reedijk M; Stambolic V; Goodwin PJ
Breast Cancer Res Treat; 2012 Oct; 135(3):821-30. PubMed ID: 22933030
[TBL] [Abstract][Full Text] [Related]
3. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
Campagnoli C; Pasanisi P; Abbà C; Ambroggio S; Biglia N; Brucato T; Colombero R; Danese S; Donadio M; Venturelli E; Zito G; Berrino F
Clin Breast Cancer; 2012 Jun; 12(3):175-82. PubMed ID: 22607767
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
Decensi A; Puntoni M; Pruneri G; Guerrieri-Gonzaga A; Lazzeroni M; Serrano D; Macis D; Johansson H; Pala O; Luini A; Veronesi P; Galimberti V; Dotti MC; Viale G; Bonanni B
Cancer Prev Res (Phila); 2011 Aug; 4(8):1181-9. PubMed ID: 21685235
[TBL] [Abstract][Full Text] [Related]
5. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
6. Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.
DeCensi A; Puntoni M; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Lazzeroni M; Vingiani A; Gentilini O; Petrera M; Viale G; Cuzick J; Bonanni B; Pruneri G
Cancer Prev Res (Phila); 2015 Oct; 8(10):888-94. PubMed ID: 26276754
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.
DeCensi A; Puntoni M; Gandini S; Guerrieri-Gonzaga A; Johansson HA; Cazzaniga M; Pruneri G; Serrano D; Schwab M; Hofmann U; Mora S; Aristarco V; Macis D; Bassi F; Luini A; Lazzeroni M; Bonanni B; Pollak MN
Breast Cancer Res Treat; 2014 Nov; 148(1):81-90. PubMed ID: 25253174
[TBL] [Abstract][Full Text] [Related]
8. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
10. Insulin-lowering effects of metformin in women with early breast cancer.
Goodwin PJ; Pritchard KI; Ennis M; Clemons M; Graham M; Fantus IG
Clin Breast Cancer; 2008 Dec; 8(6):501-5. PubMed ID: 19073504
[TBL] [Abstract][Full Text] [Related]
11. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
12. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P
Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
[TBL] [Abstract][Full Text] [Related]
13. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
15. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
Trolle B; Lauszus FF; Frystyk J; Flyvbjerg A
Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin.
Biarnés J; Fernández-Real JM; Fernández-Castañer M; del Mar García M; Soler J; Ricart W
Metabolism; 2005 Feb; 54(2):235-9. PubMed ID: 15690319
[TBL] [Abstract][Full Text] [Related]
18. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
[TBL] [Abstract][Full Text] [Related]
20. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
Glueck CJ; Goldenberg N; Sieve L; Wang P
Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
